Acurx Pharmaceuticals, Inc. ACXP
1.04 USD +0.02 (+1.96%)
Nov 4, 2026, 2:50 PM EST
1.02 Day range 1.08
1.01 52-week range 7.54
- YTD
- -58.23%
- 1 year
- -78.42%
- Market cap
- 5.69M
- EPS (ttm)
- -2.67
- Shares out
- 16.89M
- Forward P/E
- -0.56
- YTD return
- -58.23%
- 1-year return
- -78.42%
- Volume
- 82.59K
- Avg volume
- 120.46K
- Open
- 1.07
- Previous close
- 1.02
- Day's range
- 1.02 – 1.08
- 52-week range
- 1.01 – 7.54
- Beta
- -1.72
- Analysts
- Buy
- Price target
- 11.19 (+976.0%)
- Earnings date
- Aug 9, 2024
2Y -35.96 (-97.19%)
Key statistics
- Enterprise value
- 23.69M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.96M
- Total cash
- 6.36M
- Total debt
- 0
- Return on equity
- -346.94%
- Short % of float
- 3.43%
- 50-day average
- 1.46
- 200-day average
- 2.00
Analyst view
Consensus: buy
Buy
Price target (mean) 11.19 +976.0% upside
Now 1.04
- Target (low)
- 10.00
- Target (mean)
- 11.19
- Target (high)
- 12.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -0.18.
Financials — quick view
ACXP Revenue — quarterly 0
ACXP Net income — quarterly -2.25M
ACXP EPS — quarterly -0.53
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.23 | -0.17 | +0.06 | +26.09% |
| Aug 9, 2024 | Jun 1, 2024 | -0.28 | -0.26 | +0.02 | +7.14% |
| Aug 9, 2024 | Jun 1, 2024 | -0.28 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.24 | -0.28 | -0.04 | -16.67% |
| May 14, 2024 | Mar 1, 2024 | -0.24 | — | — | — |
| Mar 15, 2024 | Dec 1, 2023 | -0.26 | -0.38 | -0.12 | -46.15% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 19, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Feb 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- acurxpharma.com
News
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect 
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target 
Acurx Pharmaceuticals Says First Patient Enrolled In New PATHFINDER Clinical Trial In Patients With Multiply Recurrent C. Difficile Infection 
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection 
Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call 
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. - 12 Health Care Stocks Moving In Monday's Intraday Session
FDA Conditionally Accepts Acurx Pharmaceuticals' Brand Name CIFBEZY for Ibezapolstat
Your note
Sign in to keep a note on ACXP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DELUCCIA ROBERT J | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jan 2, 2024 | 964,782 |
| LUCI DAVID P | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 2, 2024 | 1,098,280 |
| SAILER CARL | Director | Conversion of Exercise of derivative security | Jan 18, 2024 | 117,552 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.13% | 529,349 | 463.18K | Sep 29, 2024 |
| Prospect Financial Services LLC | 1.75% | 295,075 | 258.19K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.87% | 146,500 | 128.19K | Sep 29, 2024 |
| LPL Financial LLC | 0.27% | 44,780 | 39.18K | Sep 29, 2024 |
| Morgan Stanley | 0.27% | 46,201 | 40.42K | Sep 29, 2024 |
| State Street Corporation | 0.26% | 43,466 | 38.03K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.27% | 383,812 | 335.83K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.86% | 145,537 | 127.34K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 77,312 | 67.65K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 24,876 | 21.77K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 20,030 | 17.53K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 18,296 | 16.01K | Oct 30, 2024 |